Today: 21 May 2026
Browse Category

NASDAQ:INTU 5 July 2025 - 16 November 2025

Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

‘No Tax on Tips’ Won’t Help Everyone: D.C. Emergency Tax Bill and State Rules Shrink 2025 Breaks on Overtime and Seniors

Washington, D.C. passed an emergency bill on Nov. 16, 2025, blocking new federal tax breaks for tips, overtime, and seniors at the local level. City officials acted as D.C. faces over $1 billion in projected revenue losses tied to federal job cuts. The move means residents cannot claim these deductions on their D.C. taxes despite federal law.
16 November 2025
·
Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

Tax Refunds 2025: IRS Shutdown Delays, Bigger Payouts & Global Rebate Roundup

A federal funding lapse in late October 2025 forced the IRS to pause most paper refunds, though e-filers continued receiving payments. The IRS paid $311.6 billion in refunds for 2025, averaging $3,052 per taxpayer. New tax law raised credits for children and seniors, with analysts forecasting an $50 billion surge in refunds in early 2026. Virginia announced one-time rebates; India faces refund delays; Taiwan issued a NT$10,000 cash payment.
30 October 2025
··
AI Revolution: 21 Game-Changing Tools Transforming Small Businesses in 2025

AI Revolution: 21 Game-Changing Tools Transforming Small Businesses in 2025

Ninety-three percent of small business owners in 2025 report AI tools save money and increase profitability. Jasper, Canva, HubSpot, Mailchimp, Google Analytics 4, QuickBooks, Xero, Zoho Books, and Notion AI offer AI-driven features for marketing, design, CRM, analytics, finance, and productivity, with plans ranging from free tiers to paid subscriptions starting at $10–$49 per month.
5 July 2025
······
1 … 4 5 6

Stock Market Today

  • Scotiabank Shares Showing 32% Undervaluation at C$108 Amid Strong Returns
    May 20, 2026, 10:05 PM EDT. Scotiabank (TSX:BNS) stock has rallied to around C$108.50, delivering a 59.4% return over the past year and nearly 79% over five years highlighting strong performance. Despite this, valuation models suggest substantial remaining upside. Simply Wall St's Excess Returns analysis estimates the bank's intrinsic value at approximately C$160 per share, indicating it is 32.2% undervalued compared to current prices. This model calculates excess returns by comparing the bank's return on equity to its cost of equity, reflecting efficient shareholder profit generation. Investors are closely watching key fundamentals including balance sheet resilience and dividend yield as Scotiabank navigates evolving interest rate environments. The stock's valuation score of 4 out of 6 suggests moderate confidence among analysts that price gains can continue.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop